Legend Biotech Corporation

NasdaqGS:LEGN Stock Report

Market Cap: US$9.2b

Legend Biotech Past Earnings Performance

Past criteria checks 0/6

Legend Biotech's earnings have been declining at an average annual rate of -18.4%, while the Biotechs industry saw earnings growing at 19.7% annually. Revenues have been growing at an average rate of 60.1% per year.

Key information

-18.4%

Earnings growth rate

-6.7%

EPS growth rate

Biotechs Industry Growth17.0%
Revenue growth rate60.1%
Return on equity-24.6%
Net Margin-62.5%
Last Earnings Update30 Jun 2024

Recent past performance updates

Recent updates

Legend Biotech: Entering Accelerated Growth Phase, Carvykti Positions Company For Valuation Expansion

Sep 18

Optimistic Investors Push Legend Biotech Corporation (NASDAQ:LEGN) Shares Up 26% But Growth Is Lacking

Aug 01
Optimistic Investors Push Legend Biotech Corporation (NASDAQ:LEGN) Shares Up 26% But Growth Is Lacking

Legend Biotech's Promising CAR-T Therapies Face Valuation And Cash Burn Challenges

Jul 30

Rock star Growth Puts Legend Biotech (NASDAQ:LEGN) In A Position To Use Debt

Jul 05
Rock star Growth Puts Legend Biotech (NASDAQ:LEGN) In A Position To Use Debt

Legend Biotech's Carvykti Faces Stiff Challenges Despite Advances

May 14

Some Shareholders Feeling Restless Over Legend Biotech Corporation's (NASDAQ:LEGN) P/S Ratio

May 13
Some Shareholders Feeling Restless Over Legend Biotech Corporation's (NASDAQ:LEGN) P/S Ratio

Legend Biotech: AdCom Documents Shed Light On Carvykti's Problems (Downgrade)

Mar 15

Is Legend Biotech (NASDAQ:LEGN) A Risky Investment?

Mar 06
Is Legend Biotech (NASDAQ:LEGN) A Risky Investment?

Legend Biotech: Solid Traction With Carvykti Rollout

Jan 29

Legend Biotech Corporation's (NASDAQ:LEGN) Share Price Not Quite Adding Up

Jan 16
Legend Biotech Corporation's (NASDAQ:LEGN) Share Price Not Quite Adding Up

Is Legend Biotech (NASDAQ:LEGN) A Risky Investment?

Nov 09
Is Legend Biotech (NASDAQ:LEGN) A Risky Investment?

Is Legend Biotech (NASDAQ:LEGN) Weighed On By Its Debt Load?

Apr 12
Is Legend Biotech (NASDAQ:LEGN) Weighed On By Its Debt Load?

An Intrinsic Calculation For Legend Biotech Corporation (NASDAQ:LEGN) Suggests It's 44% Undervalued

Dec 14
An Intrinsic Calculation For Legend Biotech Corporation (NASDAQ:LEGN) Suggests It's 44% Undervalued

Legend Biotech wins approval of Carvykti for multiple myeloma in Japan

Sep 27

Legend Biotech stock slides on proposed ADS offering

Jul 25

Legend Biotech ends Phase 1 trial for lymphoma candidate

Jul 07

News Flash: Analysts Just Made A Notable Upgrade To Their Legend Biotech Corporation (NASDAQ:LEGN) Forecasts

Jun 05
News Flash: Analysts Just Made A Notable Upgrade To Their Legend Biotech Corporation (NASDAQ:LEGN) Forecasts

Legend Biotech (NASDAQ:LEGN) Has Debt But No Earnings; Should You Worry?

May 14
Legend Biotech (NASDAQ:LEGN) Has Debt But No Earnings; Should You Worry?

Here's What Analysts Are Forecasting For Legend Biotech Corporation (NASDAQ:LEGN) After Its Full-Year Results

Mar 22
Here's What Analysts Are Forecasting For Legend Biotech Corporation (NASDAQ:LEGN) After Its Full-Year Results

Legend Biotech: Carvykti Approval Makes For A Buy Opportunity

Mar 04

Legend Biotech Corporation (NASDAQ:LEGN) Analysts Are More Bearish Than They Used To Be

Mar 03
Legend Biotech Corporation (NASDAQ:LEGN) Analysts Are More Bearish Than They Used To Be

Is Legend Biotech (NASDAQ:LEGN) Weighed On By Its Debt Load?

Dec 30
Is Legend Biotech (NASDAQ:LEGN) Weighed On By Its Debt Load?

Revenue & Expenses Breakdown

How Legend Biotech makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NasdaqGS:LEGN Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 24456-2852330
31 Mar 24343-4662170
31 Dec 23285-5182010
30 Sep 23233-5091910
30 Jun 23165-5321840
31 Mar 23112-5171800
31 Dec 22117-4461740
30 Sep 22106-416192-227
30 Jun 2296-457181-155
31 Mar 22119-346161313
31 Dec 2169-4041500
30 Sep 2193-356113294
30 Jun 2189-29797285
31 Mar 2180-34085184
31 Dec 2075-266730
30 Sep 2059-31055231
30 Jun 2064-27146210
31 Mar 2061-16538189
01 Jan 2062-10232162
31 Dec 1849-3461
31 Dec 1724928

Quality Earnings: LEGN is currently unprofitable.

Growing Profit Margin: LEGN is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: LEGN is unprofitable, and losses have increased over the past 5 years at a rate of 18.4% per year.

Accelerating Growth: Unable to compare LEGN's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: LEGN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (0.5%).


Return on Equity

High ROE: LEGN has a negative Return on Equity (-24.59%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies